Connect with us

Health

Know About AbbVie Inc (NYSE:ABBV)’s SELECT-MONOTHERAPY

Published

on

AbbVie Inc (NYSE:ABBV) reported that SELECT-MONOTHERAPY is a Phase III, multicenter, double-blind, randomized, parallel-group trial intended to assess the efficacy and safety of upadacitinib monotherapy in patients with moderate-to-severe rheumatoid arthritis. This patients’ group have exhibited an inadequate response to methotrexate dose. Patients were randomized to switch to upadacitinib monotherapy for 15 mg or 30 mg administered once daily from methotrexate or continue on their previous methotrexate dose in a blinded manner.

The details

AbbVie reported that the primary endpoints of this first phase comprised the percentage of subjects recording an ACR20 response and LDA after 14 weeks of therapy. Secondary endpoints comprised proportion of subjects achieving ACR70, ACR50 and clinical remission at week fourteen. The study is ongoing and the next phase marks as a blinded long-term addition period to assess the long-term tolerability, efficacy and safety of the 15 mg and 30 mg once-daily doses of upadacitinib monotherapy in subjects who have completed the initial phase.

The robust SELECT Phase III rheumatoid arthritis plan assess over 4,000 people suffering from moderate to severe rheumatoid arthritis in 6 trials. The studies comprise assessments of efficacy, tolerability and safety across multiple RA patient populations. Major measures of efficacy assessed comprise ACR responses, DAS28-CRP and inhibition of radiographic advancement. More data on these studies can be seen at www.clinicaltrials.gov.

Developed and discovered by AbbVie, upadacitinib marks as an investigational oral agent intended to selectively inhibit JAK1. As it is known, it plays a vital role in the pathophysiology of RA and other immune-mediated inflammatory problems.6-7 Phase III studies of upadacitinib in psoriatic arthritis are underway and it is even being assessed to treat ulcerative colitis, Crohn’s disease, atopic dermatitis and ankylosing spondylitis.

In the last trading session, the stock price of AbbVie declined 0.31% on traded share volume of 1.87 million to close the day at $97.79

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of MMJReporter.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure

BRANDS

DETAILS

SCORE

PRODUCT SITES

  • Certified Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49

9.8

30% OFF Today! “30 0FF”

  • All Natural
  • Made In U.S.A
  • Lab Tested
  • Price From $69

9.7

  • All Natural
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99

9.6

  • All Natural
  • Made In U.S.A
  • Oral Mist
  • Price From $39

9.5

BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49
SCORE

9.8

PRODUCT SITE
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Lab Tested
  • Price From $69
SCORE

9.7

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99
SCORE

9.6

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Oral Mist
  • Price From $39
SCORE

9.5

PRODUCT SITE VIEW PRODUCTS
Advertisement

Symbol        Alert        High        Gain

 

  VBIO          $0.67       $4.10      500%

  IMLFF        $0.11       $0.57      400%

  CMXC        $0.25       $0.45      80%

  REPCF       $0.54       $0.79      48%

 

Get Your Latest Winner Delivered to Your Inbox!

FREE

For The Next 48 Hours

Advertisement
Advertisement
Advertisement
Advertisement
Advertisement